Exagen Inc. Prepares for Upcoming Financial Results Call

Exagen Inc. Plans to Release Quarterly Financial Results

Exagen Inc. (Nasdaq: XGN), a prominent player in autoimmune diagnostics, has announced that it will release its financial results for the second quarter of 2025. This anticipated announcement is scheduled for the morning of July 29, 2025, prior to market opening. The results are expected to reflect the company’s ongoing commitment to innovating in the field of autoimmune testing.

Conference Call Details

On the same day, John Aballi, the President and CEO of Exagen, alongside Chief Financial Officer Jeff Black, will lead a conference call at 8:30 a.m. ET. This call aims to provide insights into the company’s financial performance and the strategic measures being adopted to navigate the complexities of the market.

How to Participate in the Call

For those interested in participating, they can join by dialing 201-389-0918 for U.S. callers or +1-877-407-0890 for international participants. If you prefer a digital format, a link for the webcast will be available on the Exagen investor relations website, ensuring wider access for stakeholders.

Replay Information

A replay of the conference call will be accessible until August 12, 2025. Interested parties can listen to the recording by calling 201-612-7415 in the U.S. or +1-877-660-6853 internationally using the passcode 13753132. Furthermore, a recording of the webcast will also be available about an hour after the live call concludes, which allows for anyone who missed the initial conversation to catch up on the insights shared.

About Exagen Inc.

Exagen Inc., headquartered in San Diego County, California, is at the forefront of autoimmune diagnostics. Their commitment is to transform care for individuals battling chronic autoimmune conditions by providing clarity in decision-making and improving clinical outcomes through their extensive portfolio of innovative tests. One of their main products, AVISE® CTD, is instrumental in enabling healthcare providers to diagnose complex conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome accurately and efficiently.

Innovative Testing Solutions

The suite of AVISE-branded tests offered by Exagen supports healthcare professionals in diagnosing, predicting disease outcomes, and monitoring patient progress. This dedication to research and innovation positions Exagen as a leader in addressing the challenges faced in autoimmune disease management.

Commitment to Patient-Centered Care

Exagen’s focus remains on enhancing patient care through education, innovation, and comprehensive testing solutions. The company's approach aims not only to help patients but also to aid clinicians in making informed decisions, reflecting a dedication to the overall improvement of patient health and well-being.

Contact Information

For any inquiries related to Exagen's upcoming results or their diagnostic services, interested individuals can reach out to Ryan Douglas at Exagen Inc. via email at ir@exagen.com or call 760.560.1525 for assistance.

Frequently Asked Questions

When will Exagen Inc. announce its financial results?

Exagen Inc. plans to announce its financial results for the second quarter of 2025 on July 29, 2025, before the market opens.

Who will be presenting during the conference call?

The conference call will feature John Aballi, President and CEO, and Jeff Black, Chief Financial Officer of Exagen.

How can I access the conference call?

Participants can dial 201-389-0918 for U.S. callers or +1-877-407-0890 internationally to join the call.

Will there be a replay of the conference call?

Yes, a replay will be available until August 12, 2025. You can access it by calling 201-612-7415 in the U.S. using the passcode 13753132.

What is the mission of Exagen Inc.?

Exagen Inc. is committed to transforming care for patients with chronic autoimmune conditions through innovative testing and an emphasis on patient-centered strategies.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.